{"entity":{"id":"nct02197169","kind":"trial","name":"DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors","aka":[],"tldr":"A phase 1 trial of DNX-2401 run by DNAtrix, Inc., completed.","summary":"DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors is a phase 1 interventional study registered as NCT02197169 by DNAtrix, Inc., with 37 participants enrolled, started 2014-09-11. Conditions recorded: Glioblastoma or Gliosarcoma. Interventions recorded: Single intratumoral injection of DNX-2401 and Interferon-gamma.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT02197169","url":"https://clinicaltrials.gov/study/NCT02197169"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":["dnx-2401"],"companies":["dnatrix"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02197169","phase":"1","setting":"A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)","sponsor":"DNAtrix, Inc.","enrolled":37,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02197169/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"drug":[{"id":"dnx-2401","kind":"drug","name":"DNX-2401","route":"/drugs/dnx-2401/"}],"company":[{"id":"dnatrix","kind":"company","name":"DNAtrix","route":"/companies/dnatrix/"}]}}